gemtuzumab ozogamicin

Type: Product
Name: gemtuzumab ozogamicin
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Q&A: Why is a drug being removed from our CDM?

Q: Our charge description master (CDM) manager wants to remove the code for denileukin from our CDM, as the status is changing. Why is this happening?   A: CMS is changing the status indicator for the HCPCS code for denileukin (J9160), effective October ... [Published HCPro - Sep 26 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Immunotherapy in Pediatric Malignancies

Shusterman S, London WB, Gillies SD et al. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) Phase II study. J. Clin. Oncol. 28(33), 4969–4975 (2010).Yu AL, Gilman AL, Ozkaynak MF et ... [Published General Medicine eJournal - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Novel Therapies on the Horizon in AML

Roland Walter, MD, PhDTreatment advancements for patients with acute myeloid leukemia (AML) are few and far between with marginal gains being made in the form of changes in current standard therapies or supportive care. However, several promising targeted ... [Published OncLive - Sep 18 2014]
Entities: Antibody, Mutation, Antigen
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Patent Issued for Antibody Having Anti-Cancer Activity

By a News Reporter-Staff News Editor at Life Science Weekly -- From Alexandria, Virginia , NewsRx journalists report that a patent by the inventors Kajikawa, Masunori (Komagane, JP); Sugiura, Masahito (Komagane, JP); Atarashi, Kazuyuki (Komagane, JP); ... [Published 4 Traders - Sep 18 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Emerging Approaches in Acute Myeloid Leukemia

Figures:Hugo F. Fernandez, MDThe future of AML sees us aggressively treating this disease in induction and consolidation. Molecular targets are being discovered, and directed therapy will hopefully improve upon remission rates and overall survival in ... [Published The ASCO Post - Sep 02 2014]
First reported Jul 31 2014 - Updated Jul 31 2014 - 1 reports

B7-H3L cell surface antigen and antibodies that bind thereto

The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human ... [Published PharmCast - Jul 31 2014]

Quotes

...explained AML researcher Roland Walter, MD, PhD, of the clinical research division, Fred Hutchinson Cancer Research Center, Seattle, Washington. "However, this progress is largely due to improvements in supportive care rather than the introduction of many new agents.”"

More Content

All (6) | News (6) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Q&A: Why is a drug being removed from our CDM? [Published HCPro - Sep 26 2014]
Immunotherapy in Pediatric Malignancies [Published General Medicine eJournal - Sep 19 2014]
Novel Therapies on the Horizon in AML [Published OncLive - Sep 18 2014]
Patent Issued for Antibody Having Anti-Cancer A... [Published 4 Traders - Sep 18 2014]
Emerging Approaches in Acute Myeloid Leukemia [Published The ASCO Post - Sep 02 2014]
B7-H3L cell surface antigen and antibodies that... [Published PharmCast - Jul 31 2014]
1
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.